IMP welcomes European Commission approval of KYGEVVI® for TK2d
European Commission approves KYGEVVI® for TK2d IMP warmly welcomes the decision by the European Commission to approve KYGEVVI® (doxecitine and doxribtimine) as […]
TK2d
EMA grants positive CHMP opinion for KYGEVVI® for Treatment of TK2d
EMA grants positive CHMP opinion for Kygevvi® for Treatment of TK2d International Mito Patients (IMP) and the global mitochondrial disease community
IMP Welcomes FDA Approval of First-Ever Treatment for TK2d
IMP Welcomes FDA Approval of First-Ever Treatment for TK2d International Mito Patient (IMP) is delighted to welcome yesterday’s approval by
Updated TK2d infographics to download
Help raise awareness of the symptoms of TK2D by sharing our fantastic infographics. We’ve slightly updated these from 2023, so please do replace your older graphics with these ones.
Download the version in English or landscape version in English, or follow the links for versions in Italian, Spanish, and German: